A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the tolerability of the study drug LY3039478 in Japanese participants with advanced solid tumors.
Advanced Solid Tumor
DRUG: LY3039478
Number of Participants with LY3039478 Dose-Limiting Toxicities (DLTs), Cycle 1 (28 days)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3039478, Cycle 1 Day 1 through Cycle 2 Day 1 (28 day cycles)|PK: Area Under the Curve (AUC) of LY3039478, Cycle 1 Day 1 through Cycle 2 Day 1 (28 day cycles)|Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR), Baseline through Disease Progression or Death (estimated at up to 9 months)
The purpose of this study is to evaluate the tolerability of the study drug LY3039478 in Japanese participants with advanced solid tumors.